Enhertu and the ADC Revolution — Why Antibody-Drug Conjugates Are the Most Important Development in Cancer Treatment in 2026

In December 2019 the FDA approved a new cancer medicine that most oncologists had never heard of. By 2024 it had become the best-selling antibody-drug conjugate in the world — generating USD 3.75 billion in annual sales. By early 2026 it had received Priority Review for yet another new indication and was being described by […]